PHARMA MAR, S.A. «...2122232425...» Page 21 out of 27 07/01/2021 18:14 PHARMA MAR, S.A. Liquidity and counterparty agreements The Company reports details of the operations of the Liquidity Agreement between 30/09/2020 and 31/12/2020 Register number: 6509 11/12/2020 13:55 PHARMA MAR, S.A. On corporate governance The Company informs of the substitution of the individual representative of the director Rosp Corunna Participaciones Empresariales, S.L., its resignation as member of the Audit Committee and the modification of the Board of Directors' Regulations. Register number: 6153 27/11/2020 08:24 PHARMA MAR, S.A. Total number of voting rights and capital Total number of voting rights and capital after capital reduction by means of the redemption of treasury shares. Register number: 5898 24/11/2020 08:48 PHARMA MAR, S.A. On business and financial situation The Company reports that its subsidiary Genomica, S.A.U., has obtained a CE marking for a new multiviral PCR test for COVID-19, Influenza A and B and Respiratory Syncytial Virus (RSV) diagnostic. Register number: 5843 23/11/2020 17:40 PHARMA MAR, S.A. Other relevant information Registration within the Madrid Mercantile Registry of the resolution to reduce capital by means of the redemption of own shares. Register number: 5839 03/11/2020 08:08 PHARMA MAR, S.A. Interim management report La sociedad remite declaración intermedia de gestión del tercer trimestre de 2020 Register number: 5450 28/10/2020 19:27 PHARMA MAR, S.A. On financial instruments Implementation of the reduction of share capital by means of the redemption of own shares approved by the General Shareholders´ Meeting of 18 June 2020 under item number three of the agenda. Register number: 5331 28/10/2020 12:31 PHARMA MAR, S.A. Other relevant information The Company announces the judgement of the General Court of the European Union in relation to the refusal of the marketing authorisation for plitidepsin. Register number: 5307 15/10/2020 08:29 PHARMA MAR, S.A. On business and financial situation PharmaMar signs an agreement with Jazz Pharmaceuticals to commercialize lurbinectedin in Canada Register number: 5026 29/09/2020 19:11 PHARMA MAR, S.A. Share buy-back , stabilisation and treasury stock programmes - Liquidity and counterparty agreements The company reports the transactions performed in the context of the Share Buy-back Program between 23 September and 25 September 2020. Ending of the Share Buy-back Program and resumption of the liquidity agreement. Register number: 4737 Page 21 out of 27 «...2122232425...»
